Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 28.31% is 101% above its 5-year average of -3169.41%, near the high end of its 5-year range (-9623.70%–82.67%).
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2024 (2024-03-31): 82.67%.
EBITDA MARGIN
28.31%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
-3169.41%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kiora Pharmaceuticals, Inc.
Market Cap
$11.30M
EBITDA Margin
28.31%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
-3169.41%
Market Cap
$11.44M
EBITDA Margin
-42476.19%
TTM Avg
-23876.87%
3Y Avg
-47050.54%
5Y Avg
-38398.83%
Market Cap
$11.08M
EBITDA Margin
-284.92%
TTM Avg
-261.31%
3Y Avg
-2315.78%
5Y Avg
-2461.07%
Market Cap
$11.54M
EBITDA Margin
-2404.23%
TTM Avg
-2020.23%
3Y Avg
-5031.76%
5Y Avg
-7490.37%
Market Cap
$11.52M
EBITDA Margin
-19.85%
TTM Avg
-31.46%
3Y Avg
-46.77%
5Y Avg
-56.23%
Market Cap
$10.84M
EBITDA Margin
-10625.29%
TTM Avg
-6424.40%
3Y Avg
-6424.40%
5Y Avg
-6424.40%
Market Cap
$11.62M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kiora Pharmaceuticals, Inc. (KPRX) | $11.30M | 28.31% | N/A | N/A | -3169.41% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.44M | -42476.19% | -23876.87% | -47050.54% | -38398.83% |
| BioVie Inc. (BIVI)vs › | $11.12M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.08M | -284.92% | -261.31% | -2315.78% | -2461.07% |
| Pluri Inc. (PLUR)vs › | $11.54M | -2404.23% | -2020.23% | -5031.76% | -7490.37% |
| Biofrontera Inc. (BFRI)vs › | $11.52M | -19.85% | -31.46% | -46.77% | -56.23% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.84M | -10625.29% | -6424.40% | -6424.40% | -6424.40% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.69M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.62M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| Lifeward Ltd. (LFWD)vs › | $10.57M | -75.15% | -68.19% | -159.10% | -185.14% |
Gross Margin
0.0%
EBITDA Margin
28.3%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2024-03-31 | 82.67% |
| 2020-12-31 | -9623.70% |
| 2019-03-31 | 32.80% |
| 2018-09-30 | -1007.39% |
| 2018-06-30 | -1152.98% |
| 2018-03-31 | -216.34% |
| 2017-09-30 | -5536.53% |
| 2017-06-30 | -2240.38% |
| 2017-03-31 | -1579.71% |
| 2016-12-31 | -2304.99% |
| 2016-09-30 | -1231.02% |
| 2016-06-30 | -1630.83% |
